Controlled Substances

1. Topic Overview

Controlled substances are drugs regulated by the federal Controlled Substances Act (CSA) due to their potential for abuse and physical or psychological dependence. For the Family Nurse Practitioner (FNP), this is one of the highest-stakes areas of Advanced Pharmacology. You must balance effective patient care (pain management, anxiety, ADHD) with stringent legal, ethical, and safety requirements.

On the FNP certification exam, controlled substance prescribing is heavily tested. You must know the scheduling system, refill rules, and key safety measures to avoid exam traps related to legal boundaries and overdose prevention.

2. Key Concepts and Definitions

DEA Schedules (I-V)

The DEA classifies controlled substances based on their accepted medical use, abuse potential, and safety profile. Memorizing this table is essential for exam success.

Schedule Definition High-Yield Examples Prescribing Rules (FNP)
Schedule I No accepted medical use, high abuse potential. Heroin, LSD, Marijuana (federal), Ecstasy Cannot be prescribed. Used only for research.
Schedule II High abuse potential with severe dependence liability. Accepted medical use. Morphine, Oxycodone, Fentanyl, Adderall, Ritalin, Methadone (for pain) Written or electronic prescription required. No refills. Limited to a 30-day supply per fill.
Schedule III Moderate to low potential for physical dependence. High psychological dependence possible. Tylenol #3 (Codeine), Testosterone, Ketamine May be prescribed orally or electronically. Up to 5 refills allowed within 6 months.
Schedule IV Low abuse potential relative to Schedule III. Xanax, Ativan, Valium, Ambien, Tramadol May be prescribed orally or electronically. Up to 5 refills allowed within 6 months.
Schedule V Lowest abuse potential. Contains limited quantities of narcotics. Robitussin AC (Codeine), Lyrica, Lomotil Prescriber discretion. Some states allow OTC sale at pharmacy.

Core Terminology

  • Tolerance: A pharmacologic state where a higher dose of a drug is required to achieve the same effect (e.g., needing 20 mg of Oxycodone instead of 10 mg).
  • Physical Dependence: An adaptive physiologic state characterized by withdrawal symptoms upon abrupt discontinuation, dose reduction, or administration of an antagonist.
  • Addiction (Substance Use Disorder): A primary, chronic disease characterized by impaired control over drug use, craving, and continued use despite harm. Dependence ≠ Addiction.
  • Pseudo-addiction: Behavior resembling addiction driven by undertreated pain. Resolves once adequate pain control is established. Key clinical distinction.
  • Agonist: Binds to a receptor and produces a response (e.g., Morphine at the mu-opioid receptor).
  • Antagonist: Binds to a receptor and blocks it, producing no response (e.g., Naloxone at the mu-opioid receptor).

3. Core Principles and Processes

The DEA Number

  • FNPs must obtain their own DEA registration number to prescribe controlled substances.
  • Structure: 2 letters + 7 digits.
    • First letter: Registrant type (e.g., B=hospital, M=mid-level provider).
    • Second letter: First letter of the registrant's last name.
    • Check digit: Verify this for forgery detection. (Add 1st, 3rd, 5th digits; add 2nd, 4th, 6th digits x2; sum mod 10 must equal the check digit).
  • Renewal: Required every 3 years.

Prescribing Rules by Schedule

  • Schedule II:
    • Must be a written prescription or electronic prescription from a registered prescriber.
    • No refills. A new prescription is required for each fill.
    • Emergency dispensing: Verbal order allowed for a 72-hour supply only.
    • Partial fills: Allowed during a shortage, but must be completed within 72 hours.
  • Schedule III-V:
    • May be prescribed orally, electronically, or by fax.
    • Up to 5 refills allowed within 6 months from the date of issue.
    • After 6 months, a new prescription is required.

The X-Waiver (Historical Context)

  • High-Yield: The X-Waiver (DATA 2000 waiver) was previously required to prescribe buprenorphine for Opioid Use Disorder (OUD).
  • Current Law (MAT Act of 2022): The X-Waiver has been eliminated. Any DEA-registered practitioner (including FNPs) with Schedule III authority can now prescribe buprenorphine for OUD without a separate waiver.
  • Exception: Individual state laws regarding MOUD still apply. Check your state board of nursing.

Telemedicine and Controlled Substances

  • Ryan Haight Act: Generally requires an in-person medical evaluation before prescribing controlled substances via telemedicine.
  • Public health emergency (PHE) flexibilities allowed telemedicine prescribing of buprenorphine without an initial in-person visit. These flexibilities are now permanent under the SUPPORT Act for OUD treatment.

4. Signs, Symptoms, and Features of Misuse

  • Red Flags for Aberrant Behavior:
    • Frequent "lost" or "stolen" prescriptions.
    • Unscheduled visits for early refills.
    • Insisting on specific brand-name opioids (e.g., OxyContin).
    • Running out of medication early on multiple occasions.
    • Suspicious urine drug screen (UDS) results.
    • Prescription forgery or "doctor shopping."
  • Signs of Opioid Toxicity:
    • Miosis (pinpoint pupils).
    • Respiratory depression (rate < 8/min).
    • Sedation or obtundation (difficult to arouse).

5. Assessment, Diagnosis, and Evaluation

Risk Stratification Tools

  • SOAPP-R (Screener and Opioid Assessment for Patients with Pain-Revised): Self-administered questionnaire to predict risk for aberrant behaviors.
  • ORT (Opioid Risk Tool): Rapid assessment tool categorizing patients as low, moderate, or high risk for opioid misuse. High-Yield.
  • CAGE-AID: Alcohol and drug screening questionnaire. (Felt the need to Cut down, Annoyed by criticism, Guilty, Eye-opener).

Urine Drug Screening (UDS) Interpretation

  • Purpose: Confirm adherence and detect use of non-prescribed substances.
  • Immunoassay (Screening): Rapid, less specific. Prone to false positives (e.g., poppy seeds for opiates, some SSRIs for benzodiazepines).
  • Gas Chromatography/Mass Spectrometry (Confirmation): Gold standard. Used to confirm positive screening results.
  • High-Yield Pitfalls:
    • Opiates vs. Opioids: Immunoassay screens for "opiates" (morphine, codeine). Semisynthetic opioids like oxycodone, hydrocodone, and fentanyl are NOT detected on a standard opiate screen. You must order a specific "opioid panel" or "expanded opiate screen."
    • Buprenorphine: Requires a specific immunoassay; it is not detected on a standard opiate screen.

Prescription Drug Monitoring Program (PDMP)

  • A statewide electronic database containing all controlled substance prescriptions dispensed to a patient.
  • FNP Action: Check the PDMP before initiating a new controlled substance and at least every 3-6 months thereafter.
  • Exam Tip: Failure to check the PDMP is a common cause of disciplinary action against FNPs.

6. Treatment, Interventions, and Patient Care

Safe Prescribing for Pain (Acute & Chronic)

  • Start with Non-Opioids: Maximize NSAIDs (naproxen, ibuprofen), acetaminophen, gabapentinoids (gabapentin, pregabalin), and topical agents (lidocaine).
  • Non-Pharmacologic Therapies: Physical therapy, cognitive behavioral therapy (CBT), acupuncture, mindfulness.
  • Lowest Effective Dose: If an opioid is indicated, start with the lowest effective dose of an immediate-release product for the shortest duration (typically 3-7 days for acute pain).
  • Morphine Milligram Equivalents (MME):
    • Calculating daily MME is critical for assessing overdose risk.
    • Threshold: > 50 MME/day doubles the overdose risk. > 90 MME/day is the FDA "caution zone" for chronic prescribing.
    • Action: Consider naloxone co-prescribing, avoiding benzodiazepines, and more frequent monitoring for patients above 50 MME.

Medication for Opioid Use Disorder (MOUD)

  • Buprenorphine (Suboxone, Zubsolv):
    • Partial mu-opioid agonist. Ceiling effect for respiratory depression (safer than methadone).
    • Induction: Patient must be in moderate withdrawal (COWS score > 8) before first dose to avoid precipitated withdrawal.
    • No X-Waiver required.
  • Naltrexone (Vivitrol):
    • Full mu-opioid antagonist. Blocks the euphoric effects of opioids.
    • Requires 7-14 days of opioid abstinence before initiation.
    • Poor adherence with oral form. Extended-release injectable (Vivitrol) is preferred for alcohol and OUD.
  • Methadone:
    • Full mu-opioid agonist. Used for OUD detoxification/maintenance.
    • FNP Limitation: Methadone for OUD CANNOT be prescribed by FNPs. It must be dispensed daily from a federally regulated Opioid Treatment Program (OTP).
    • Methadone can be prescribed for pain (Schedule II), but requires significant expertise due to QTc prolongation and variable half-life.

7. Safety Precautions and Complications

Naloxone (Narcan) Co-Prescribing

  • Indications (High-Yield):
    • Daily MME > 50.
    • Concurrent use of benzodiazepines or CNS depressants.
    • History of opioid overdose or substance use disorder.
    • Presence of high-risk medical conditions (sleep apnea, COPD).
    • Patient on any schedule II opioid for chronic pain (some guidelines recommend universal co-prescribing).

Major Drug Interactions

  • CNS Depression: Opioids + Benzodiazepines + Alcohol = Respiratory arrest. Avoid concurrent prescribing whenever possible. If unavoidable, counsel heavily and cap MME.
  • Serotonin Syndrome: Tramadol, Meperidine (Demerol), and Methadone + SSRIs, SNRIs, MAOIs = agitation, hyperthermia, clonus.
  • QTc Prolongation: Methadone is the highest risk. Obtain a baseline EKG, then repeat at 30 days and annually.
  • CYP450 Interactions: Codeine and Tramadol are prodrugs (act via CYP2D6). Poor metabolizers (lack enzyme) get no effect; ultra-rapid metabolizers get toxic levels (high risk for respiratory depression in children).

8. Exam Tips and High-Yield Points

  • Schedule II Refill Rule: No refills. A new prescription must be written for each fill.
  • Schedule III-V Refill Rule: Up to 5 refills within 6 months.
  • X-Waiver Gone: Buprenorphine can now be prescribed by any DEA-registered practitioner with Schedule III authority for OUD. No separate waiver is required.
  • Methadone Rule: Methadone for OUD is only dispensed at an OTP (clinic). FNPs cannot prescribe it for addiction, only for pain (under state protocol).
  • Naloxone Co-Prescribing: Always think of this when MME > 50 or patient is on a benzodiazepine.
  • MME Threshold: > 50 MME = increased risk. > 90 MME = caution zone. These are common exam numbers.
  • UDS Pitfall: Standard "opiate" screens do NOT detect oxycodone, fentanyl, or buprenorphine. Order an "extended opioid panel."
  • Patient Agreement: For chronic opioid therapy, you must use a Controlled Substance Agreement (pain contract) outlining responsibilities, urine drug screens, pill counts, and grounds for discontinuation.
  • Memory Aid for Serotonin Syndrome: "Shivering, Hyperthermia, Autonomic instability, Klonus (myoclonus), Encephalopathy."